3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
18
Unknown
15
Recruiting
6
Terminated
4
Not yet recruiting
2
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
17
Breast
13
Thoracic
7
Genitourinary
7
Head & Neck
4
CNS
4
Sarcoma
3
Endocrine
2
Dermatologic
2
Tumor-Agnostic
1
NET
1
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
1
Neoplasm Metastasis
1
Interventions
pembrolizumab
45
Paclitaxel
45
Carboplatin
39
Magnetic Resonance Spectroscopy
28
olaparib
27
Specimen Handling
26
Cisplatin
24
Bevacizumab
20
Nivolumab
18
Taxes
17
Biopsy
16
Gemcitabine
13
Cyclophosphamide
13
durvalumab
12
Immunoglobulin G
11
Doxorubicin
11
Disulfides
11
Surveys and Questionnaires
10
niraparib
9
liposomal doxorubicin
9
dostarlimab
9
Radiotherapy
8
Brachytherapy
8
lenvatinib
7
fludarabine
7
atezolizumab
7
Letrozole
7
Docetaxel
7
cediranib
6
Platinum
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Surgical Procedures, Operative
×
Gynecologic
×
Clear all
NCT05081609
2026-02-24
IL Believe
Ascendis Pharma A/S
Phase 1/2
Active not recruiting
320 enrolled